Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

20-09-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial results

print
PRINT
insite
SEARCH

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08)

Receive weekly updates on the diabetes news that matters to you

Register for the e-alert!


External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the interview transcript

Back to the EASD 2019 conference hub

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content

20-09-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

13-06-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

15-04-2019 | Nephropathy | Highlight | News

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

29-07-2019 | Pathophysiology | News

Cluster analysis may help to predict diabetic complications
Image Credits